Mora, J., Perez-Jaume, S., Varo, A., Simao, M., Heredia, A. C., Chamorro, S., Muñoz, J. P., Gorostegui, M., Lopez, S., Larrosa, C. (2025). Irinotecan, temozolomide and naxitamab plus GM-CSF (HITS) and naxitamab plus GM-CSF and ifosfamide, carboplatin, etoposide (NICE) for patients with relapsed or refractory high-risk neuroblastoma: A single center, open-label phase 2 clinical trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.10039